Dr. Hill on Future Research With CAR T-Cell Therapy in B-Cell Lymphomas

Video

Brian T. Hill, MD, PhD, discusses future research with CAR T-cell therapy in hematologic malignancies.

Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician, Taussig Cancer Institute, and assistant professor, Hematology and Oncology, Cleveland Clinic, discusses future research with CAR T-cell therapy in hematologic malignancies.

​In the B-cell lymphoma space, lisocabtagene maraleucel ​(liso-cel) appears to be associated with low rates of severe CAR T-cell therapy–related toxicities, ​Hill says.

Additionally, future research efforts should compare the efficacy and safety profiles of tisagenlecleucel (Kymriah), ​liso-cel, and axicabtagene ciloleucel (Yescarta), ​explains Hill. Further investigation may also shed light on subtle differences in the makeup of each product.

Ultimately, sorting out the unique characteristics ​of the 3 products will help the field identify which patients will benefit most from each ​therapy, Hill concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.